The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Epilepsy Drug Market Research Report 2024

Global Epilepsy Drug Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1414021

No of Pages : 87

Synopsis
Epilepsy is a chronic brain disorder characterized by sudden and recurrent episodes of seizure.
The global Epilepsy Drug market was valued at US$ 1839.1 million in 2023 and is anticipated to reach US$ 2031.8 million by 2030, witnessing a CAGR of 1.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Epilepsy Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Epilepsy Drug.
Report Scope
The Epilepsy Drug market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Epilepsy Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Epilepsy Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Eisai
Novartis
Sanofi
Union Chimique Belge
Abbott
GlaxoSmithKline
Sunovion Pharmaceuticals
Teva Pharmaceutical
Johnson & Johnson
Abbvie
Janssen Pharmaceuticals
Cephalon
Segment by Type
First Generation Drugs
Second Generation Drugs
Third Generation Drugs
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Epilepsy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Epilepsy Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Epilepsy Drug Market Overview
1.1 Product Overview and Scope of Epilepsy Drug
1.2 Epilepsy Drug Segment by Type
1.2.1 Global Epilepsy Drug Market Value Comparison by Type (2024-2030)
1.2.2 First Generation Drugs
1.2.3 Second Generation Drugs
1.2.4 Third Generation Drugs
1.3 Epilepsy Drug Segment by Application
1.3.1 Global Epilepsy Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Epilepsy Drug Market Size Estimates and Forecasts
1.4.1 Global Epilepsy Drug Revenue 2019-2030
1.4.2 Global Epilepsy Drug Sales 2019-2030
1.4.3 Global Epilepsy Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Epilepsy Drug Market Competition by Manufacturers
2.1 Global Epilepsy Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Epilepsy Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Epilepsy Drug Average Price by Manufacturers (2019-2024)
2.4 Global Epilepsy Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Epilepsy Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Epilepsy Drug, Product Type & Application
2.7 Epilepsy Drug Market Competitive Situation and Trends
2.7.1 Epilepsy Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Epilepsy Drug Players Market Share by Revenue
2.7.3 Global Epilepsy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Epilepsy Drug Retrospective Market Scenario by Region
3.1 Global Epilepsy Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Epilepsy Drug Global Epilepsy Drug Sales by Region: 2019-2030
3.2.1 Global Epilepsy Drug Sales by Region: 2019-2024
3.2.2 Global Epilepsy Drug Sales by Region: 2025-2030
3.3 Global Epilepsy Drug Global Epilepsy Drug Revenue by Region: 2019-2030
3.3.1 Global Epilepsy Drug Revenue by Region: 2019-2024
3.3.2 Global Epilepsy Drug Revenue by Region: 2025-2030
3.4 North America Epilepsy Drug Market Facts & Figures by Country
3.4.1 North America Epilepsy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Epilepsy Drug Sales by Country (2019-2030)
3.4.3 North America Epilepsy Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Epilepsy Drug Market Facts & Figures by Country
3.5.1 Europe Epilepsy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Epilepsy Drug Sales by Country (2019-2030)
3.5.3 Europe Epilepsy Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Epilepsy Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Epilepsy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Epilepsy Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Epilepsy Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Epilepsy Drug Market Facts & Figures by Country
3.7.1 Latin America Epilepsy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Epilepsy Drug Sales by Country (2019-2030)
3.7.3 Latin America Epilepsy Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Epilepsy Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Epilepsy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Epilepsy Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Epilepsy Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Epilepsy Drug Sales by Type (2019-2030)
4.1.1 Global Epilepsy Drug Sales by Type (2019-2024)
4.1.2 Global Epilepsy Drug Sales by Type (2025-2030)
4.1.3 Global Epilepsy Drug Sales Market Share by Type (2019-2030)
4.2 Global Epilepsy Drug Revenue by Type (2019-2030)
4.2.1 Global Epilepsy Drug Revenue by Type (2019-2024)
4.2.2 Global Epilepsy Drug Revenue by Type (2025-2030)
4.2.3 Global Epilepsy Drug Revenue Market Share by Type (2019-2030)
4.3 Global Epilepsy Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Epilepsy Drug Sales by Application (2019-2030)
5.1.1 Global Epilepsy Drug Sales by Application (2019-2024)
5.1.2 Global Epilepsy Drug Sales by Application (2025-2030)
5.1.3 Global Epilepsy Drug Sales Market Share by Application (2019-2030)
5.2 Global Epilepsy Drug Revenue by Application (2019-2030)
5.2.1 Global Epilepsy Drug Revenue by Application (2019-2024)
5.2.2 Global Epilepsy Drug Revenue by Application (2025-2030)
5.2.3 Global Epilepsy Drug Revenue Market Share by Application (2019-2030)
5.3 Global Epilepsy Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Epilepsy Drug Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Eisai
6.2.1 Eisai Corporation Information
6.2.2 Eisai Description and Business Overview
6.2.3 Eisai Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eisai Epilepsy Drug Product Portfolio
6.2.5 Eisai Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Novartis Epilepsy Drug Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Epilepsy Drug Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Union Chimique Belge
6.5.1 Union Chimique Belge Corporation Information
6.5.2 Union Chimique Belge Description and Business Overview
6.5.3 Union Chimique Belge Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Union Chimique Belge Epilepsy Drug Product Portfolio
6.5.5 Union Chimique Belge Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Abbott Epilepsy Drug Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 GlaxoSmithKline
6.6.1 GlaxoSmithKline Corporation Information
6.6.2 GlaxoSmithKline Description and Business Overview
6.6.3 GlaxoSmithKline Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline Epilepsy Drug Product Portfolio
6.7.5 GlaxoSmithKline Recent Developments/Updates
6.8 Sunovion Pharmaceuticals
6.8.1 Sunovion Pharmaceuticals Corporation Information
6.8.2 Sunovion Pharmaceuticals Description and Business Overview
6.8.3 Sunovion Pharmaceuticals Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sunovion Pharmaceuticals Epilepsy Drug Product Portfolio
6.8.5 Sunovion Pharmaceuticals Recent Developments/Updates
6.9 Teva Pharmaceutical
6.9.1 Teva Pharmaceutical Corporation Information
6.9.2 Teva Pharmaceutical Description and Business Overview
6.9.3 Teva Pharmaceutical Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Teva Pharmaceutical Epilepsy Drug Product Portfolio
6.9.5 Teva Pharmaceutical Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Corporation Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Johnson & Johnson Epilepsy Drug Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 Abbvie
6.11.1 Abbvie Corporation Information
6.11.2 Abbvie Epilepsy Drug Description and Business Overview
6.11.3 Abbvie Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Abbvie Epilepsy Drug Product Portfolio
6.11.5 Abbvie Recent Developments/Updates
6.12 Janssen Pharmaceuticals
6.12.1 Janssen Pharmaceuticals Corporation Information
6.12.2 Janssen Pharmaceuticals Epilepsy Drug Description and Business Overview
6.12.3 Janssen Pharmaceuticals Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Janssen Pharmaceuticals Epilepsy Drug Product Portfolio
6.12.5 Janssen Pharmaceuticals Recent Developments/Updates
6.13 Cephalon
6.13.1 Cephalon Corporation Information
6.13.2 Cephalon Epilepsy Drug Description and Business Overview
6.13.3 Cephalon Epilepsy Drug Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Cephalon Epilepsy Drug Product Portfolio
6.13.5 Cephalon Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Epilepsy Drug Industry Chain Analysis
7.2 Epilepsy Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Epilepsy Drug Production Mode & Process
7.4 Epilepsy Drug Sales and Marketing
7.4.1 Epilepsy Drug Sales Channels
7.4.2 Epilepsy Drug Distributors
7.5 Epilepsy Drug Customers
8 Epilepsy Drug Market Dynamics
8.1 Epilepsy Drug Industry Trends
8.2 Epilepsy Drug Market Drivers
8.3 Epilepsy Drug Market Challenges
8.4 Epilepsy Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’